Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Biovie Inc. BIVI

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$-22.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 14-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -150.8%
-200%-400%
201220182025
Three returns, three denominators.

Each USD of equity lost 151 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks

Total assetsUSD 14.3M
EquityUSD 10.3M
CashUSD 9.0M
Current ratio3.59×

Equity funds 72% of total assets.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BIVI, 14-year financial record
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Income tax $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.1−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−3.05−12.12−73.05−15.47−1.06−14.82−6.85−0.98−0.03−0.010.000.000.000.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————
ROE %−150.8−101.6−208.3−528.7−598.2——−218.0−383.8−86.6——−97.2−3.6
Shares out B0.010.000.010.040.020.020.010.000.100.090.090.090.090.09

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures · 2 divergences in 52 reconciliationsAUDITED

Reconciled in 10 of the 14 fiscal years we could check. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 10 checks were skipped: the balance sheet is not tagged before 2012. Five checks were skipped: EPS is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures2 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image